

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions of claims in the subject application.

Claim 1 (currently amended): A solid ionic conjugate comprising a basic pharmaceutical compound and a functional polymer, wherein: (a) said basic pharmaceutical compound is poorly soluble in water having a water solubility of less than about 1 mg/ml and is less soluble than said solid ionic conjugate and (b) said functional polymer is acidic and is selected from the group consisting of a carboxyl bearing copolyester carbonates and carboxyl-bearing polyesters made by ring-opening polymerization of one or more cyclic monomers lactide (L), glycolide (G), p-dioxanone (PD),  $\epsilon$ -caprolactone (CL), 1,5-dioxepan-2-one (DOP), and trimethylene carbonate (TMC); and carboxyl-bearing polypeptides.

Claim 2 (canceled):

Claim 3 (currently amended): The solid ionic conjugate of claim 1 wherein said functional polymer is a carboxyl-bearing cyclodextrin water insoluble derivative made by mixed partial acylation of cyclodextrin with a fatty acid anhydride and a cyclic anhydride, followed by grafting the unacylated hydroxylic group of said cyclodextrin with one or more cyclic monomers selected from glycolide, lactide, ~~p-dioxanone~~ p-dioxanone, ~~1,5-dioxepan-2-dione~~ 1,5-dioxepan-2-one,  $\epsilon$ -caprolactone, and trimethylene carbonate.

Claim 4 (original): The solid ionic conjugate of claim 1 wherein said pharmaceutical compound is an aryl-heterocyclic compound.

Claim 5 (original): The solid ionic conjugate of claim 4 wherein said pharmaceutical compound is ziprasidone.

Claim 6 (original): A pharmaceutical composition comprising the ionic conjugate of claim 1 and a pharmaceutically acceptable vehicle.

Claim 7 (original): The pharmaceutical composition of claim 6 wherein said pharmaceutically acceptable vehicle is for controlled release or immediate release of said pharmaceutical compound.

Claim 8 (currently amended): The pharmaceutical composition of claim 6 wherein the functional polymer comprises: i) an absorbable copolyester made by ring-opening polymerization of one or more of cyclic monomers selected from glycolide, lactide, trimethylene carbonate, p-dioxanone, ~~1,5-dioxepan-2-dione~~ 1,5-dioxepan-2-one, and  $\epsilon$ -caprolactone; or ii) a carboxyl-bearing, water-insoluble cyclodextrin derivative made by a mixed partial acylation of cyclodextrin with a fatty acid anhydride and a cyclic anhydride, followed by grafting the unacylated hydroxylic group of said cyclodextrin with one or more of the following cyclic monomers: glycolide, lactide, p-dioxanone, ~~1,5-dioxepan-2-dione~~ 1,5-dioxepan-2-one,  $\epsilon$ -caprolactone, and trimethylene carbonate.

Claim 9 (currently amended): The pharmaceutical composition of ~~claim 4~~ claim 6 wherein the vehicle comprises: i) an absorbable gel-forming liquid; or ii) a vegetable oil.

Claim 10 (currently amended): The pharmaceutical composition of ~~claim 4~~ claim 6 wherein said pharmaceutical compound is ziprasidone; said functional polymer comprises: i) an absorbable copolyester made by ring-opening polymerization of one or more cyclic monomers selected from glycolide, lactide, trimethylene carbonate, p-dioxanone, ~~1,5-dioxepan-2-dione~~ 1,5-dioxepan-2-one, and  $\epsilon$ -caprolactone; or ii) a carboxyl-bearing, water-insoluble cyclodextrin derivative made by a mixed partial acylation of cyclodextrin with a fatty acid anhydride and a cyclic anhydride, followed by grafting the unacylated hydroxylic group of said cyclodextrin with one or more cyclic monomers selected from glycolide, lactide, p-dioxanone, ~~1,5-dioxepan-2-dione~~ 1,5-dioxepan-2-one,  $\epsilon$ -caprolactone, and trimethylene carbonate; and said vehicle comprises: i) an absorbable gel-forming liquid; or ii) a vegetable oil.

Claim 11 (original): A process for preparing the solid ionic conjugate of claim 1 wherein said pharmaceutical compound and a functional polymer are dissolved in an organic solvent and the ionic conjugate in substantially dry form is obtained after removing the solvent by distillation or sublimation under reduced pressure.

Claim 12 (canceled):

Claim 13 (original): The process of claim 11 wherein said pharmaceutical compound is an aryl-heterocyclic compound.

Claim 14 (original): The process of claim 13 wherein said pharmaceutical compound is ziprasidone free base.

Claim 15 (original): The process of claim 11 wherein said pharmaceutical compound is ziprasidone; and said functional polymer comprises: i) an absorbable copolyester made by ring-opening polymerization of one or more cyclic monomers selected from glycolide, lactide, trimethylene carbonate, p-dioxanone, ~~1,5-dioxapan-2-dione~~ 1,5-dioxepan-2-one, and  $\epsilon$ -caprolactone; or ii) a carboxyl-bearing, water-insoluble cyclodextrin derivative made by a mixed partial acylation of cyclodextrin with a fatty acid anhydride and a cyclic anhydride, followed by grafting the unacylated hydroxylic group of said cyclodextrin with one or more of the following cyclic monomers: glycolide, lactide, p-dioxanone, ~~1,5-dioxapan-2-dione~~ 1,5-dioxepan-2-one,  $\epsilon$ -caprolactone, and trimethylene carbonate; and said organic solvent is hexafluoro-isopropanol.

Claim 16 (new): The solid ionic conjugate of claim 1 wherein said functional polymer comprises a cyclodextrin.

Claim 17 (new): The solid ionic conjugate of claim 1 wherein said functional polymer comprises a cyclic oligosaccharide derivative with carboxyl groups on the outer surface.